ÂÜÀòÂÒÂ×

August Moretti joined our Board in April 2019. He is currently the CFO of 4D Molecular Technologies, a privately held gene therapy company. Augie has extensive operating and financial executive experience in all phases of company growth and funding, from early stage development to product approval and commercialization. From 2012 to 2018 he was CFO of Assertio Therapeutics, a publicly held specialty pharmaceuticals company focused in pain and neurology, and from 2004 to 2011 CFO of Alexza Pharmaceuticals, a publicly held pharmaceutical company developing drug device combination products for pulmonary delivery of CNS drugs. From 2001 to 2004 he was CFO and General Counsel of Surromed, a privately held biotechnology company focused on proteomics. Prior to 2001 he was a partner of Heller Ehrman, an international law firm, where his practice included representation of life science companies on issues relating to public and private financings, mergers and acquisitions, corporate governance, disclosure and public reporting.

As CFO of Assertio, Alexza and Surromed he has raised over $1.5 billion in funding, including public and private issuance of equity, convertible debt and secured debt and monetization of royalty interests, has overseen several product acquisitions and has been responsible for 50 consecutive quarters of public company reporting.

Augie holds a B.A. in Economics from Princeton University and a J.D. from Harvard Law School and has taught Finance at UC Berkeley School of Business Administration.